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 Abstract 
  Background/Aims:   While experimental models that emulate diabetic nephropathy are valu-
able tools for elucidating pathogenetic mechanisms and developing novel therapies, existing 
models imperfectly recapitulate human disease. In diabetes, hyperglycemia and hemodynam-
ic forces act in concert to induce renal injury. Accordingly, in the present study, we combined 
streptozotocin-induced diabetes with surgical ablation of 5/6 of the kidney mass with the aim 
of evaluating their additive effects on renal function and glomerular morphology.   Methods:  
Female F344 rats were randomized to undergo subtotal nephrectomy (SNx) either at baseline 
or following 4 weeks of diabetes.  Results:  In comparison to sham rats, rats with diabetes or rats 
after SNx surgery, diabetic subtotally nephrectomized (DM-SNx) rats demonstrated an increase 
in systolic blood pressure, glomerular volume and mesangial matrix. Albuminuria was synergis-
tically increased by hyperglycemia and renal mass ablation associated with decreased nephrin 
expression. In contrast, glomerular capillary rarefaction and glomerular filtration rate were sim-
ilarly reduced in SNx and DM-SNx rats.   Conclusion:   The DM-SNx rat recapitulates some of the 
features of human disease, most notably augmented albuminuria. Since this model avoids the 
deletion or overexpression of gene(s) linked to the pathogenesis of nephropathy, the DM-SNx 
rat model represents a complementary tool for the trial of novel therapies. 
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 Introduction 
  One of the major limitations to the study of pathogenetic mechanisms in diabetic ne-
phropathy is the lack of a rodent model that reproducibly develops renal disease analogous 
to that seen in human patients. In recent years, technological advances in genetic manipula-
tion have enabled the generation of promising experimental models lacking in (or overex-
pressing) genes inextricably linked to the progression of the condition   [1]  . While undoubt-
edly an advance, such models possess limitations when it comes to their use in the develop-
ment and testing of novel therapies. Although deletion of a particular gene may accelerate 
renal injury in diabetes, its absence may also render a promising experimental therapy inef-
fective if such a therapy’s mechanism of action is reliant on the affected pathway   [2]  .
    Hypertension is present in approximately 70% of individuals with diabetes   [3]   and is an 
independent predictor of the future risk of both the development and progression of renal 
disease  [4] . Such epidemiological evidence, together with the well-documented beneficial ef-
fects of anti-hypertensive therapy   [5, 6]  , pays testament to the synergistic relationship be-
tween hyperglycemia and hemodynamic forces in mediating renal decline. One well-de-
scribed and well-established means of inducing renal injury as a consequence of hemody-
namic stress is the surgical ablation of 5/6 of the renal mass (subtotal nephrectomy, SNx). 
Although landmark studies of ACE inhibition testify to this model’s pedigree in pharmaceu-
tical development   [7]  , the absence of hyperglycemia limits its applicability to the diabetic 
setting. In this context, we sought to develop a novel rodent model of renal disease by per-
forming SNx surgery in rats with pre-existing streptozotocin (STZ)-induced diabetes.
  M e t h o d s  
 Animals 
  Female Fischer (F344) rats aged 8 weeks were randomized to undergo either SNx or 
sham surgery (n = 8–12/group) as previously described   [8]  . Following an 8-hour fast, diabe-
tes was induced with a single intraperitoneal injection of STZ (45 mg/kg in 0.1   M   citrate buf-
fer pH 4.5), 4 weeks before SNx surgery, and animals were followed for 8 weeks after renal 
mass ablation. Blood glucose was determined weekly and 1 unit of insulin (Humulin N iso-
phane; Eli Lilly, Toronto, Ont., Canada) was administered subcutaneously (s.c.) if blood glu-
cose was greater than 32 m  M  . Diabetic rats received 1 unit of insulin 48 h prior to surgery. 
Peri-operative fluid management consisted of the administration of Ringer’s lactate solution 
s.c. 5–10 ml immediately pre-operatively, 3–4 ml post-operatively and 5 ml daily for the next 
2 days. HbA  1c  was determined using A1cNow+ (Bayer, Sunnyvale, Calif., USA). The glomer-
ular filtration rate (GFR) was determined by FITC-inulin clearance as previously described 
  [8]  . Urine albumin excretion was determined using AssayMax Rat Albumin ELISA kit (As-
saypro, St. Charles, Mo., USA). Systolic blood pressure (SBP) was measured with a 2F micro-
manometer (Model SPR-838; Millar Instruments, Houston, Tex., USA) and analyzed using 
Chart Software v5.6 (AD Instruments, Bella Vista, N.S.W., Australia). All experimental pro-
cedures adhered to the guidelines of the Canadian Council on Animal Care and were ap-
proved by the St. Michael’s Hospital Animal Care Committee.
  Immunohistochemistry 
  Immunohistochemistry was performed as previously described   [8–11]   with antibodies 
in the following concentrations: JG-12 1:     1,000 (Bender MedSystems GmbH, Vienna, Aus-
tria), nephrin 1:     500 (R&D Systems, Minneapolis, Minn., USA), WT1 1:     1,000 (Santa Cruz 
Biotechnology, Santa Cruz, Calif., USA) and collagen IV 1:     100 (Southern Biotech, Birming-117
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ham, Ala., USA). Kidney sections were scanned with the Aperio ScanScope system (Aperio 
Technologies Inc., Vista, Calif., USA) and analyzed using ImageScope (Aperio Technologies 
Inc.). For the determination of capillary density and nephrin, the proportional glomerular 
area of positive immunostaining was determined in 30 randomly selected glomerular pro-
files from each kidney section  [8, 10] . Glomerular nuclei positively immunostaining for WT1 
were quantified in 30 glomerular profiles from each kidney section as previously described 
  [9]  . Cortical tubulointerstitial collagen IV was determined as the proportional cortical area 
positively immunostaining in six random non-overlapping fields   ! 100  magnification.
  Glomerular  Volume 
  The glomerular volume was calculated on PAS-stained kidney sections (30 glomerular 
profiles from each rat) as described previously   [11]  .
  Glomerulosclerosis  Index 
  The magnitude of glomerulosclerosis was calculated from at least 50 glomeruli in PAS-
stained kidney sections using a semi-quantitative scoring system as previously described  [8, 9] .
  S t a t i s t i c s  
 Data are expressed as means  8  SEM. Statistical significance was determined by one-way 
ANOVA with Newman-Keuls post-test. Two-way ANOVA was performed for assessing the 
interaction between STZ-induced diabetes and SNx. All statistical analyses were performed 
using GraphPad Prism 5 for Mac OS X (GraphPad Software Inc., San Diego, Calif., USA).
  R e s u l t s  
  Development of the DM-SNx Model 
  We anticipated that concurrent STZ-induced diabetes and SNx surgery would adversely 
affect mortality and therefore selected a rat sex and strain (female F344 rats) in which renal 
mass ablation would induce comparatively mild disease. In pilot studies, urine protein excre-
tion in female F344 rats was approximately one-third of that seen in male Sprague Dawley 
animals 8 weeks after SNx surgery (urine protein excretion in mg/24 h: male Sprague Daw-
ley SNx 109.61   !  /  &   1.5, female F344 SNx 30.93   !  /  &   1.4, p   !   0.05). To allow recovery from 
acute development of hyperglycemia, SNx surgeries were performed 4 weeks after diabetes 
induction. 
    Renal Function in DM-SNx Rats 
  Following our initial exploratory studies, four groups of rats were studied: sham-oper-
ated rats (sham), subtotally nephrectomized rats (SNx), STZ-diabetic rats (DM) and STZ-
diabetic rats that underwent SNx surgery (DM-SNx) ( table 1 ). Eight weeks after sham or SNx 
surgery, there was no difference in glycemic control between DM and DM-SNx rats. SNx 
surgery resulted in an increase in SBP in non-diabetic and a larger increase in diabetic SNx 
rats (  table 1  ). Whereas GFR was increased in DM rats, consistent with the hyperfiltrative 
phase of diabetic nephropathy, it was reduced in rats after renal mass ablation (  table 1  ). The 
combination of diabetes and SNx did not cause a greater decrease in GFR than SNx alone 
(  table 1  ). In contrast, while albuminuria was minimally increased in DM rats and moder-
ately increased in SNx rats, it was markedly and synergistically augmented with the combi-
nation of diabetes and SNx in DM-SNx rats (  fig. 1  ).118
Nephron Extra 2012;2:115–124
 DOI:  10.1159/000338272 
  Published online: May 12, 2012 
EXTRA
  Chen et al.: Nephropathy in the Diabetic Subtotally Nephrectomized Rat 
www.karger.com/nne
    © 2012 S. Karger AG, Basel
    Glomerulosclerosis, Glomerular Volume and Glomerular Capillary Density in 
DM-SNx Rats 
  Despite a minimal rise in albuminuria in DM rats relative to sham rats, mesangial ma-
trix deposition was notably increased (  table 2  ;   fig. 2  ). However, in contrast to the segmental 
distribution of glomerulosclerosis observed in SNx rats, matrix deposition in DM animals 
was diffusely distributed throughout the glomerulus (  table 2  ). The glomerulosclerosis index 
was increased in DM-SNx relative to either DM or SNx rats alone, primarily as a consequence 
of an increase in the number of glomeruli showing areas of moderate or severe sclerosis (  ta-
ble 2  ). The glomerular volume was increased after SNx surgery and was augmented in the 
Table 1. F  unctional characteristics of sham-operated, DM, SNx and DM-SNx rats
Body weight 
g
Left kidney 
weight, g
Left kidney 
weight:body
weight, %
HbA1c
%
SBP 
mm Hg
GFR 
ml/min/kg
Sham 18583 0.5780.01 0.3180.01 4.580.1 11084 5.780.3
DM 13184a 0.6080.03 0.5480.02a 11.080.2a 12786 7.680.4h
SNx 17184b 0.6380.04 0.3880.03b 4.380.1b 14485f 2.880.4a, b
DM-SNx 12685a, c 0.7580.03a, d, e 0.6080.03a, c 11.780.7a, c 166812a, d, g 3.180.5a, b
a  p < 0.001 vs. sham, b p < 0.001 vs. DM, c p < 0.001 vs. SNx, d p < 0.01 vs. DM, e p < 0.05 vs. SNx, f p < 
0.01 vs. sham, g p < 0.05 vs. SNx, h p < 0.05 vs. sham.
  Fig. 1.   Albumin excretion rate in 
sham-operated, DM, SNx and 
DM-SNx rats.   *  p   !   0.001 vs. all 
other groups. p   !   0.001 for inter-
action. 
Table 2. G lomerulosclerosis index (GSI) and the percentage of glomeruli with glomerulosclerosis in sham-
operated, DM, SNx and DM-SNx rats
GSI Grade 0
0%
Grade 1
1–25% 
Grade 2
26–50%
Grade 3
51–75%
Grade 4
76–100%
Sham 0.3480.04 66.484.1 33.284.1 0.480.2 00
DM 0.9680.09a 18.285.3 67.884.8 13.584.2 0.480.3 0
SNx 1.0280.14a 26.685.6 54.085.0 13.683.5 2.581.0 3.582.0
DM-SNx 2.0580.31b 8.982.6 32.888.7 20.884.4 19.784.6 17.888.5
G  lomerulosclerosis grade determined as the estimated percentage of the glomerular profile affected. 
a p < 0.05 vs. sham, b p < 0.001 vs. all other groups.119
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setting of diabetes (i.e. in DM-SNx rats) (  fig. 3  ). Although the glomerular volume was in-
creased, consistent with the changes in GFR, the glomerular capillary density was reduced 
in both SNx and DM-SNx rats (  fig. 4  ). In contrast to glomerular changes in DM-SNx rats, 
tubulointerstitial fibrosis, as determined by collagen IV immunostaining, was not increased 
(proportional area of cortical tubulointerstitial collagen IV (AU): sham 0.077   8   0.007, SNx 
0.097   8   0.012, DM 0.092   8   0.012, DM-SNx 0.102   8   0.013, p = non-significant).
    Nephrin Expression and Podocyte Number in DM-SNx Rats 
  Glomerular nephrin immunostaining was markedly lower in DM-SNx rats than in the 
other three groups ( fig. 5 a–e), while the number of glomerular cells positively immunostain-
ing for the podocyte marker WT1 was similarly reduced in DM, SNx and DM-SNx rats rela-
tive to sham animals (  fig. 5  f–j).
  Discussion 
  In the present study, we observed a marked augmentation of albumin excretion in DM-
SNx rats, far above that predicted by the additive effects of renal mass ablation and hyper-
glycemia in isolation. This impairment of the filtration barrier permselectivity occurred in 
  Fig. 2.   Representative periodic 
acid-Schiff-stained kidney sec-
tions from sham-operated (  a ), 
DM (  b  ), SNx (  c  ) and DM-SNx 
( d  ) rats. Original magnification 
  ! 400. 
  Fig. 3.   G l o m e r u l a r  v o l u m e  i n  
sham-operated, DM, SNx and 
DM-SNx rats.   *  p    !   0.001 vs. 
sham,   †  p   !   0.01 vs. DM,   ‡  p   !  
0.001 vs. DM,   §  p   !   0.05 vs. SNx. 120
Nephron Extra 2012;2:115–124
 DOI:  10.1159/000338272 
  Published online: May 12, 2012 
EXTRA
  Chen et al.: Nephropathy in the Diabetic Subtotally Nephrectomized Rat 
www.karger.com/nne
    © 2012 S. Karger AG, Basel
concert with augmented glomerulomegaly and a reduction in the expression of the slit pore 
protein nephrin, reflecting the combined effects of increased intraglomerular pressures and 
hyperglycemic injury. Such accelerated renal injury may be a useful means for modeling 
some aspects of nephropathy seen in patients.
  The SNx rat is a well-characterized model of progressive proteinuric renal disease medi-
ated by the compensatory response to rising intraglomerular pressures within the remnant 
kidney  [12] . In contrast, hyperglycemia alone typically results in only minimal or mild renal 
injury in most rodent strains  [1] . Surprisingly, despite their widespread adoption in isolation, 
few studies have examined the combined effects of STZ-induced diabetes and SNx, most 
likely due to the risk of peri-operative complications in rodents with marked hyperglycemia. 
The renal injury we observed in DM-SNx rats is comparable with that induced by two-step 
removal of 3/4 of the kidney mass before STZ injection   [13–15]  , while circumventing the ad-
ministration of STZ to a renally insufficient animal.
    As with patients with diabetic nephropathy   [16]  , the SNx rat demonstrates sensitivity to 
renin-angiotensin system (RAS) blockade exceeding that expected from blood pressure low-
  Fig. 4.   Representative photomi-
crographs of JG-12-labeled glo-
merular capillaries from kidney 
sections from sham-operated ( a ), 
DM (  b ),  SNx  ( c  ) and DM-SNx 
( d  ) rats. Original magnification 
  ! 400.   e   Quantitation of JG-12 
immunolabeling.   *  p   !   0.01 vs. 
sham,   †  p   !   0.001 vs. DM,   ‡  p   !  
0.001 vs. sham. 121
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ering alone  [17] . Intriguingly, the augmented albuminuria we observed with the combination 
of hyperglycemia and renal mass ablation is remarkably consistent with that previously re-
ported in an alternative hypertensive model that combined STZ-induced diabetes with an-
giotensin II infusion   [18]  . Whether the renal injury in DM-SNx rats is sensitive to conven-
tional therapy with RAS blockade, or novel interventions, remains to be determined. One 
likely contributor to the heavy albuminuria in DM-SNx rats is the downregulation of the slit 
pore protein nephrin, which occurred independently of a decrease in podocyte number 
(WT1 immunostaining). While damage to any of the three principal layers of the glomeru-
lar filtration barrier may result in macromolecular leakage into the urinary space, over recent 
years attention has turned to a central role for podocyte injury   [19]  . Nephrin plays a pivotal 
role in maintaining the podocyte slit diaphragm  [20, 21] , and a number of reports have dem-
  Fig. 5.   Podocyte changes in DM-SNx rats. Representative photomicrographs of nephrin-immunostained 
kidney sections from sham-operated (  a  ), DM (  b  ), SNx (  c  ) and DM-SNx (  d  ) rats. Original magnification 
  ! 400.  e  Quantitation of nephrin immunostaining. Representative photomicrographs of WT1-immunos-
tained kidney sections from sham-operated (  f  ), DM (  g  ), SNx (  h  ) and DM-SNx (  i  ) rats. Original magnifi-
cation   ! 400.   j   Quantitation of WT1 immunostaining.   *  p   !   0.001 vs. sham,   †  p   !   0.05 vs. DM,   ‡  p   !   0.01 
vs. SNx,   §   p   !   0.05 vs. sham,   ¶  p   !   0.01 vs. sham. 122
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onstrated reduced nephrin expression in both experimental diabetes and after SNx as well 
as in their clinical correlates   [22–25]  .
  By employing a differential sieving approach, Kim et al.  [26]  demonstrated that nephrin 
expression was specifically reduced in hypertrophied glomeruli of diabetic rats, but not in 
smaller-sized glomeruli. Early glomerular enlargement is a feature of both nephron mass 
reduction and experimental diabetes, although the pathogenetic processes activated by these 
two experimental approaches are likely to be different   [27]  . In the present study, the glomer-
ular volume was significantly greater in DM-SNx rats than in the other three groups, sug-
gesting that enhanced glomerular enlargement may contribute to the downregulation of 
nephrin and augmented albuminuria in these animals. However, while this represents one 
pathogenetic process it is unlikely to be the sole one, given the magnitude of increase in al-
bumin excretion observed in these animals.
  Histologically, excessive accumulation of the extracellular matrix within the glomerular 
mesangium correlates most closely with GFR decline in advancing renal disease   [28]  . In the 
present study, the magnitude of glomerulosclerosis in DM and SNx rats was equivalent, al-
though its pattern of distribution was qualitatively quite different, with a diffuse increase in 
mesangial matrix deposition occurring in the former and focal glomerular injury a feature 
of the latter. While DM-SNx rats displayed an increase in the proportion of severely sclerosed 
glomeruli, the absence of accelerated GFR decline in these animals is indicative of the hy-
perfiltrative effects of hyperglycemia alone.
  Despite heavy albuminuria and augmented renal injury, like all currently available mod-
els of nephropathy the DM-SNx rat is not without its limitations. For instance, pathological 
changes were most prominent within the glomeruli. In contrast, tubulointerstitial fibrosis, 
that also correlates with advancing renal injury   [29]  , was relatively unaffected. A further 
methodological limitation is the limited tissue available (1/6 of the renal mass) for subsequent 
molecular biological and/or histological analysis. The mechanism by which renal injury was 
induced may also be argued as not being representative of the clinical setting. However, this 
is no more so than in models that rely on the mutation, deletion or overexpression of genes 
implicated in the pathogenetic process. Hemodynamic forces play a fundamental role in the 
pathogenesis of diabetic nephropathy and, in this respect, the DM-SNx rat may be viewed as 
offering advantages in modeling some aspects of diabetic nephropathy including the pres-
ence of concurrent hypertension.
    In summary, the DM-SNx rat model may be considered a complementary addition to 
the inventory of tools now available for the study of pathogenetic processes and novel thera-
pies in diabetic nephropathy.
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